SCHEMBL9924964

SCHEMBL9924964

CCCc1ccc(OC(=O)c2ccc(C3CCC4CC(COc5ccc(OCC)c(F)c5F)CCC4C3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.41
THRB P10828 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.36
SCN9A Q15858 2/20 0.35
PDE4A P27815 2/20 0.34
PDE4B Q07343 2/20 0.34
PDE4C Q08493 2/20 0.34
PDE4D Q08499 2/20 0.34
CCNC P24863 1/20 0.34
CDK8 P49336 1/20 0.34
KMT2A Q03164 2/20 0.33
RAB9A P51151 1/20 0.33
PLA2G1B P04054 1/20 0.33
ATG4B Q9Y4P1 1/20 0.33
SSTR5 P35346 1/20 0.33
KCNH2 Q12809 1/20 0.33
ACACB O00763 1/20 0.33
USP2 O75604 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924963 1.00 MAPT (0.41) MAPTTHRBSMN1; SMN2SCN9APDE4A
SCHEMBL10066571 0.90 MAPT (0.39) MAPTTHRBSMN1; SMN2CCNCCDK8
SCHEMBL19189741 0.89 MAPT (0.38) MAPTTHRBSMN1; SMN2KMT2ARAB9A
SCHEMBL9924782 0.88 SCN9A (0.35) SCN9AKMT2ASLC6A3
SCHEMBL9924962 0.87 SCN9A (0.35) SCN9ASLC6A3
SCHEMBL9925108 0.86 CYP2C9 (0.39) MAPTTHRBSMN1; SMN2CCNCCDK8
SCHEMBL9924966 0.86 SENP8 (0.34) SCN9AKMT2ARAB9AKCNH2ACACB
SCHEMBL9924967 0.86 SENP8 (0.34) SCN9AKMT2ARAB9AKCNH2ACACB
SCHEMBL9924918 0.85 SCN9A (0.34) SCN9ASSTR5KCNH2SLC6A3
SCHEMBL9925128 0.84 SCN9A (0.33) SCN9AACACBSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
US-8465674-B2 Decahydronaphthalene compound, liquid crystal composition including the compound and liquid crystal display device containing the liquid crystal composition JNC CORPORATION (JP) 2013-06-18 US disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION JNC PETROCHEMICAL CORPORATION (JP) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120145959-A1 DECAHYDRONAPHTHALENE COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE COMPOUND AND LIQUID CRYSTAL DISPLAY DEVICE CONTAINING THE LIQUID CRYSTAL COMPOSITION DCUN1D2, OCIAD1, CPNE4 MAPT 3409/4885THRB 2813/4885SMN1; SMN2 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.